Manufacturing scale‑up: Lonza expands gene‑therapy capacity — CSL builds $1.5B plasma plant

Two major manufacturing investments signal expanded capacity for complex biologics: Lonza agreed to expand commercial manufacturing to continue production of Genetix Biotherapeutics' ZYNTEGLO gene therapy at its Houston cell and gene therapy site, with provisions for future scale‑up. The move preserves a long‑standing CDMO partnership that underpins commercial supplies for transfusion‑dependent beta‑thalassemia. Separately, CSL broke ground on a $1.5 billion immunoglobulin plant in Illinois to boost plasma‑derived therapies and support growing demand for specialty immune products. CSL framed the project as a continuation of its U.S. manufacturing investments and global supply strategy. Together the announcements highlight industry priorities: secure, scalable supply chains for cell and gene therapies and plasma‑derived medicines, and continued outsourcing partnerships that link innovators with large CDMOs.